T Therapeutics
- Headquarters
- Cambridge
- Employees
- 11–50
- Founded
- 2022
- Business Model
- B2B
- Website
- t-therapeutics.com
- Total Funding
- $60.0M
- Last Round
- $60.0M Series ANov 2023
About
T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge, developing treatments for cancer and autoimmune disease. The company uses its proprietary OpTiMus platform — based on a fully humanized TCR mouse — combined with single-cell genomics, machine learning, and structural biology to generate antigen-specific human TCRs targeting previously undruggable classes.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Sign up to view funding details
Create a free account to see full funding history, valuations, and investor participation.
Create Free Account